Compare Figs Inc (FIGS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Figs Inc trades at $14.26 (market cap $2.39B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 55.6× Figs Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | VRTX | |
|---|---|---|
Market Cap | $2.39B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $529.65 |
52-Week Low | $6.57 | $376.62 |
Enterprise Value | $2.15B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock surged 26.87% to $14.26, supported by strong Q2 2026 earnings that beat estimates with $0.11 EPS and 29% revenue growth. The technical outlook is bullish with moving averages aligned positively, while fundamentals show improving profitability with a net income margin of 8.72% and robust gross margins near 69%. Recent news highlights institutional buying and raised full-year guidance, reflecting strong operational momentum.
The outlook remains positive given consistent earnings beats and upward revenue revisions, though the stock's high P/E of 43.21 suggests premium valuation risks. Key investor risks include cost pressures from tariffs and freight, alongside competitive threats in the healthcare apparel space. Analyst consensus is bullish with a $19.50 price target, indicating potential upside from current levels.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
